{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:05:03Z","timestamp":1779361503250,"version":"3.51.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Regional Science Fund project grants","award":["2022GXNSFBA035664"],"award-info":[{"award-number":["2022GXNSFBA035664"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01427-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:40:54Z","timestamp":1779352854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut Microbial Dysbiosis in Type 2 Diabetes Patients with Concurrent Atherosclerosis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-795X","authenticated-orcid":false,"given":"Abdul","family":"Sammad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohrab","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Ling","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3934-0945","authenticated-orcid":false,"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fca-2018-0045","volume":"14","author":"RJ Henning","year":"2018","unstructured":"Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol Engl. 2018;14:491\u2013509.","journal-title":"Future Cardiol Engl"},{"key":"1427_CR2","doi-asserted-by":"crossref","unstructured":"Avdic T, Carlsen HK, Rawshani A, Gudbj\u00f6rnsdottir S, Mandalenakis Z, Eliasson B. Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: an observational, register-based cohort study. Cardiovasc Diabetol. BioMed Central Ltd; 2024;23:1\u201311. Available from: https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02226-x.\u00a0 [Cited 5 Feb 2025].","DOI":"10.1186\/s12933-024-02226-x"},{"key":"1427_CR3","doi-asserted-by":"publisher","unstructured":"Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I., Eur Heart J, Oxford A. 2013;34:2436\u201343. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/eht149. [Cited 5 Feb 2025].","DOI":"10.1093\/eurheartj\/eht149"},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s42255-022-00590-0","volume":"4","author":"S Sugimoto","year":"2022","unstructured":"Sugimoto S, Mena HA, Sansbury BE, Kobayashi S, Tsuji T, Wang C-H, et al. Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation. Nat Metab Ger. 2022;4:775\u201390.","journal-title":"Nat Metab Ger"},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40842-025-00247-3","volume":"11","author":"A Hussain","year":"2025","unstructured":"Hussain A. Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus. Cardiovasc Diabetol Endocrinol Rep Engl. 2025;11:39.","journal-title":"Cardiovasc Diabetol Endocrinol Rep Engl"},{"key":"1427_CR6","first-page":"116884","volume":"176","author":"R Pal","year":"2023","unstructured":"Pal R, Bhadada SK. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review. Bone United States. 2023;176:116884.","journal-title":"Bone United States"},{"key":"1427_CR7","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lezP, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci Switz; 2023;24. https:\/\/doi.org\/10.3390\/ijms24119352.","DOI":"10.3390\/ijms24119352"},{"key":"1427_CR8","doi-asserted-by":"crossref","unstructured":"Ciubotaru PG, Kundnani NR, Sharma A, Neagu MN, Ivan VS, Buzas R et al. Hypertension and diabetes as determinants of patient-reported quality of life in permanent atrial fibrillation. Diagnostics. 2025;15. Available from: https:\/\/www.mdpi.com\/2075-4418\/15\/21\/2674.","DOI":"10.3390\/diagnostics15212674"},{"key":"1427_CR9","doi-asserted-by":"publisher","unstructured":"LiZ-H, Wang X-Y, Luo Q. The roles of advanced glycation end products in cardiovascular diseases: from mechanisms to therapeutic strategies. Front Cardiovasc Med. 2025;12. Available from: https:\/\/doi.org\/10.3389\/fcvm.2025.1637252.","DOI":"10.3389\/fcvm.2025.1637252"},{"key":"1427_CR10","doi-asserted-by":"crossref","unstructured":"Wang T, Li H, Wang C, Li X, Deng A, Jiao X. Diabetic retinopathy as a sentinel of systemic vascular dysfunction: shared molecular mechanisms with cardiovascular disease. Exp Eye Res. 2025;261:110644. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0014483525004166.","DOI":"10.1016\/j.exer.2025.110644"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2337\/dc20-2806","volume":"45","author":"A Sharma","year":"2022","unstructured":"Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care United States. 2022;45:204\u201312.","journal-title":"Diabetes Care United States"},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature12198","volume":"498","author":"FH Karlsson","year":"2013","unstructured":"Karlsson FH, Tremaroli V, Nookaew I, Bergstr\u00f6m G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nat Engl. 2013;498:99\u2013103.","journal-title":"Nat Engl"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"e9085","DOI":"10.1371\/journal.pone.0009085","volume":"5","author":"N Larsen","year":"2010","unstructured":"Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One United States. 2010;5:e9085.","journal-title":"PLoS One United States"},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00018-017-2509-x","volume":"74","author":"GA Weiss","year":"2017","unstructured":"Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci Switz. 2017;74:2959\u201377.","journal-title":"Cell Mol Life Sci Switz"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3109\/08916934.2014.938322","volume":"47","author":"J Karczewski","year":"2014","unstructured":"Karczewski J, Poniedzia\u0142ek B, Adamski Z, Rzymski P. The effects of the microbiota on the host immune system. Autoimmun Engl. 2014;47:494\u2013504.","journal-title":"Autoimmun Engl"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/dmrr.2617","volume":"31","author":"C Bleau","year":"2015","unstructured":"Bleau C, Karelis AD, St-Pierre DH, Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev Engl. 2015;31:545\u201361.","journal-title":"Diabetes Metab Res Rev Engl"},{"key":"1427_CR17","doi-asserted-by":"publisher","unstructured":"Mei Z, Wang F, Bhosle A, Dong D, Mehta R, Ghazi A et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. Nat Med. 2024;30:2265\u201376. Available from: https:\/\/doi.org\/10.1038\/s41591-024-03067-7.","DOI":"10.1038\/s41591-024-03067-7"},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13099-021-00446-0","volume":"13","author":"AL Cunningham","year":"2021","unstructured":"Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathog Engl. 2021;13:50.","journal-title":"Gut Pathog Engl"},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-025-01371-2","volume":"28","author":"JH He","year":"2025","unstructured":"He JH, Wang H, Qiu E, Qi Q, Wang Z. Gut Microbiota and Atherosclerosis: Integrative Multi-Omics and Mechanistic Insights. Curr Atheroscler Rep United States. 2025;28:1.","journal-title":"Curr Atheroscler Rep United States"},{"key":"1427_CR20","doi-asserted-by":"publisher","unstructured":"ZhangY-Y, Chen S-T, Chen G, Zhou L, Zhou G-L, Yu X-Y et al. The Type III Secretion System (T3SS) of Escherichia Coli Promotes Atherosclerosis in Type 2 Diabetes Mellitus. Adv Sci (Weinheim, Baden-Wurttemberg, Ger. Germany). 2025;e2413296. https:\/\/doi.org\/10.1002\/advs.202413296.","DOI":"10.1002\/advs.202413296"},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"109138","DOI":"10.1016\/j.biopha.2019.109138","volume":"117","author":"Q Ma","year":"2019","unstructured":"Ma Q, Li Y, Li P, Wang M, Wang J, Tang Z, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother Elsevier Masson. 2019;117:109138.","journal-title":"Biomed Pharmacother Elsevier Masson"},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"e170124225723","DOI":"10.2174\/0115733998281910231231051814","volume":"21","author":"A Al-Busaidi","year":"2024","unstructured":"Al-Busaidi A, Alabri O, Alomairi J, ElSharaawy A, Al Lawati A, Al Lawati H, et al. Gut Microbiota and Insulin Resistance: Understanding the Mechanism of Better Treatment of Type 2 Diabetes Mellitus. Curr Diabetes Rev United Arab Emirates. 2024;21:e170124225723.","journal-title":"Curr Diabetes Rev United Arab Emirates"},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1210\/jc.2015-4251","volume":"101","author":"KM Utzschneider","year":"2016","unstructured":"Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab United States. 2016;101:1445\u201354.","journal-title":"J Clin Endocrinol Metab United States"},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41467-017-00900-1","volume":"8","author":"Z Jie","year":"2017","unstructured":"Jie Z, Xia H, Zhong S-L, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun Engl. 2017;8:845.","journal-title":"Nat Commun Engl"},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"e0032422","DOI":"10.1128\/spectrum.00324-22","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, et al. Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy. Microbiol Spectr United States. 2022;10:e0032422.","journal-title":"Microbiol Spectr United States"},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract Elsevier. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract Elsevier"},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/eurheartj\/eht142","volume":"34","author":"JA Beckman","year":"2013","unstructured":"Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J Engl. 2013;34:2444\u201352.","journal-title":"Eur Heart J Engl"},{"key":"1427_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri2850","volume":"10","author":"N Cerf-Bensussan","year":"2010","unstructured":"Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol Engl. 2010;10:735\u201344.","journal-title":"Nat Rev Immunol Engl"},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1007\/s12602-024-10417-x","volume":"17","author":"X Zheng","year":"2025","unstructured":"Zheng X, Zhang Z, Shan T, Zhao M, Lu H, Zhang L, et al. Study on the Mechanism of Bifidobacterium animalis subsp. lactis F1-3-2 Regulating Bile Acid Metabolism Through TMA-TMAO Pathway to Improve Atherosclerosis. Probiotics Antimicrob Proteins United States. 2025;17:4851\u201366.","journal-title":"Probiotics Antimicrob Proteins United States"},{"key":"1427_CR30","doi-asserted-by":"publisher","first-page":"108991","DOI":"10.1016\/j.jnutbio.2022.108991","volume":"105","author":"L Anto","year":"2022","unstructured":"Anto L, Blesso CN. Interplay between diet, the gut microbiome, and atherosclerosis: Role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism. J Nutr Biochem United States. 2022;105:108991.","journal-title":"J Nutr Biochem United States"},{"key":"1427_CR31","first-page":"473","volume":"46","author":"S Jiang","year":"2026","unstructured":"Jiang S, Gong L, Zheng H. [Research progress on the correlation between Akkermansia muciniphila and cardiovascular diseases]. Nan Fang Yi Ke Da Xue Xue Bao China. 2026;46:473\u20138.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao China"},{"key":"1427_CR32","doi-asserted-by":"publisher","unstructured":"Yuan Y, Zhang J, Xu J, Xia X, Yu M, Zha L et al. Association of Decreased Fecal Microbiota Akkermansia with Increased High-Sensitivity C-Reactive Protein Levels in Patients with Unstable Angina. Curr Med Sci. 2025;45:494\u2013505. Available from: https:\/\/doi.org\/10.1007\/s11596-025-00050-2.","DOI":"10.1007\/s11596-025-00050-2"},{"key":"1427_CR33","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","volume":"51","author":"M Gurung","year":"2020","unstructured":"GurungM, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine Neth. 2020;51:102590. https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.051.","journal-title":"EBioMedicine Neth"},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nat Engl. 2012;490:55\u201360.","journal-title":"Nat Engl"},{"key":"1427_CR35","doi-asserted-by":"crossref","unstructured":"Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T et al. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection. Arterioscler Thromb Vasc Biol. 2022;42:1081\u201393. Available from: https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/ATVBAHA.121.317276.","DOI":"10.1161\/ATVBAHA.121.317276"},{"key":"1427_CR36","doi-asserted-by":"publisher","unstructured":"Zhu S, Xu K, Jiang Y, Zhu C, Suo C, Cui M et al. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology. 2022;61:258\u201369. Available from: https:\/\/doi.org\/10.1093\/rheumatology\/keab309.","DOI":"10.1093\/rheumatology\/keab309"},{"key":"1427_CR37","doi-asserted-by":"crossref","unstructured":"Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;15. Available from: https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2024.1486793.","DOI":"10.3389\/fendo.2024.1486793"},{"key":"1427_CR38","doi-asserted-by":"publisher","first-page":"2570423","DOI":"10.1080\/19490976.2025.2570423","volume":"17","author":"M Gawa\u0142ko","year":"2025","unstructured":"Gawa\u0142ko M, Kociemba W, Sanders P, Linz D. Gut microbiome and atrial fibrillation: mechanistic insights metabolites and comorbidities. Systematic review. Gut Microbes United States. 2025;17:2570423.","journal-title":"Gut Microbes United States"},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40168-023-01566-2","volume":"11","author":"Z Wang","year":"2023","unstructured":"Wang Z, Peters BA, Bryant M, Hanna DB, Schwartz T, Wang T, et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome Engl. 2023;11:119.","journal-title":"Microbiome Engl"},{"key":"1427_CR40","doi-asserted-by":"publisher","unstructured":"Karlsson FH, F\u00e5k F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. Available from: https:\/\/doi.org\/10.1038\/ncomms2266.","DOI":"10.1038\/ncomms2266"},{"key":"1427_CR41","first-page":"722","volume":"12","author":"T Rittiphairoj","year":"2021","unstructured":"Rittiphairoj T, Pongpirul K, Janchot K, Mueller NT, Li T. Probiotics Contribute to Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Adv Nutr United States. 2021;12:722\u201334.","journal-title":"Adv Nutr United States"},{"key":"1427_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/mlf2.12110","volume":"3","author":"Y Mao","year":"2024","unstructured":"Mao Y, Kong C, Zang T, You L, Wang L-S, Shen L, et al. Impact of the gut microbiome on atherosclerosis. mLife Australia. 2024;3:167\u201375.","journal-title":"mLife Australia"},{"key":"1427_CR43","doi-asserted-by":"publisher","unstructured":"Zhai L, Xiao H, Lin C, Wong HLX, Lam YY, Gong M et al. Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome. Nat Commun. 2023;14:4986. Available from: https:\/\/doi.org\/10.1038\/s41467-023-40552-y.","DOI":"10.1038\/s41467-023-40552-y"},{"key":"1427_CR44","doi-asserted-by":"publisher","unstructured":"Sayols-Baixeras S, Dekkers KF, Baldanzi G, J\u00f6nsson D, Hammar U, Lin Y-T et al. Streptococcus Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort. Circulation. American Heart Association; 2023;148:459\u201372. Available from: https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063914.","DOI":"10.1161\/CIRCULATIONAHA.123.063914"},{"key":"1427_CR45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1128\/AEM.02821-13","volume":"80","author":"K Kampoo","year":"2014","unstructured":"Kampoo K, Teanpaisan R, Ledder RG, McBain AJ. Oral bacterial communities in individuals with type 2 diabetes who live in southern Thailand. Appl Environ Microbiol United States. 2014;80:662\u201371.","journal-title":"Appl Environ Microbiol United States"},{"key":"1427_CR46","doi-asserted-by":"publisher","unstructured":"Dash NR, Al Bataineh MT, Alili R, Al Safar H, Alkhayyal N, Prifti E et al. Functional alterations and predictive capacity of gut microbiome in type 2 diabetes. Sci Rep. 2023;13:22386. Available from: https:\/\/doi.org\/10.1038\/s41598-023-49679-w","DOI":"10.1038\/s41598-023-49679-w"},{"key":"1427_CR47","doi-asserted-by":"publisher","first-page":"739093","DOI":"10.3389\/fcvm.2021.739093","volume":"8","author":"J Chen","year":"2021","unstructured":"Chen J, Qin Q, Yan S, Yang Y, Yan H, Li T, et al. Gut Microbiome Alterations in Patients With Carotid Atherosclerosis. Front Cardiovasc Med Switz. 2021;8:739093.","journal-title":"Front Cardiovasc Med Switz"},{"key":"1427_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1752-1947-8-365","volume":"8","author":"FE Al-Otaibi","year":"2014","unstructured":"Al-Otaibi FE, Al-Mohizea MM. Non-vertebral Veillonella species septicemia and osteomyelitis in a patient with diabetes: a case report and review of the literature. J Med Case Rep Engl. 2014;8:365.","journal-title":"J Med Case Rep Engl"},{"key":"1427_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1186\/s12967-024-05928-8","volume":"22","author":"S Murugesan","year":"2024","unstructured":"Murugesan S, Yousif G, Djekidel MN, Gentilcore G, Grivel JC, Al Khodor S. Microbial and proteomic signatures of type 2 diabetes in an Arab population. J Transl Med Engl. 2024;22:1132.","journal-title":"J Transl Med Engl"},{"key":"1427_CR50","doi-asserted-by":"crossref","unstructured":"Iatcu OC, Hamamah S, Covasa M. Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes. Nutrients Switz; 2024;16.","DOI":"10.3390\/nu16203447"},{"key":"1427_CR51","doi-asserted-by":"crossref","unstructured":"Bellali S, Naud S, Ndongo S, Lo CI, Anani H, Raoult D et al. Corynebacterium pacaense sp. nov., Alistipes megaguti sp. nov., Alistipes provencensis sp. nov., 3 new bacteria isolated from fresh human stool specimens. New Microbes New Infect. England; 2019;32:100593.","DOI":"10.1016\/j.nmni.2019.100593"},{"key":"1427_CR52","doi-asserted-by":"crossref","unstructured":"Park S, Zhang T, Kang S. Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes. Int J Mol Sci Switz; 2023;24.","DOI":"10.3390\/ijms24119533"},{"key":"1427_CR53","doi-asserted-by":"publisher","unstructured":"GuoX, Dai S, Lou J, Ma X, Hu X, Tu L et al. Distribution characteristics of oral microbiota and its relationship with intestinal microbiota in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14. Available from: https:\/\/doi.org\/10.3389\/fendo.2023.1119201.","DOI":"10.3389\/fendo.2023.1119201"},{"key":"1427_CR54","doi-asserted-by":"publisher","unstructured":"WangL, Fang X, Shi L, Wang P, Chen W, Yang J et al. Identification and optimized detection of two type 2 diabetes-associated enteric pathogens: Klebsiella and EPEC. BMC Infect Dis Engl; 2026;26. https:\/\/doi.org\/10.1186\/s12879-026-12786-w.","DOI":"10.1186\/s12879-026-12786-w"},{"key":"1427_CR55","doi-asserted-by":"publisher","unstructured":"Byndloss M, Devkota S, Duca F, Hendrik Niess J, Nieuwdorp M, Orho-Melander M et al. The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications\u20142023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetes Care. 2024;47:1491\u2013508. Available from: https:\/\/doi.org\/10.2337\/dci24-0052.","DOI":"10.2337\/dci24-0052"},{"key":"1427_CR56","doi-asserted-by":"crossref","unstructured":"Zhang K, Qin X, Qiu J, Sun T, Qu K, Din AU et al. Desulfovibrio desulfuricans aggravates atherosclerosis by enhancing intestinal permeability and endothelial TLR4\/NF-\u03baB pathway in Apoe\u2013\/\u2013 mice. Genes Dis. 2023;10:239\u201353. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S235230422100115X.","DOI":"10.1016\/j.gendis.2021.09.007"},{"key":"1427_CR57","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/nmeth.2658","volume":"10","author":"JN Paulson","year":"2013","unstructured":"Paulson JN, Stine OC, Bravo HC, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods United States. 2013;10:1200\u20132.","journal-title":"Nat Methods United States"},{"key":"1427_CR58","doi-asserted-by":"publisher","unstructured":"Breiman L, Random, Forests. Mach Learn. 2001;45:5\u201332. Available from: https:\/\/doi.org\/10.1023\/A:1010933404324","DOI":"10.1023\/A:1010933404324"},{"key":"1427_CR59","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2337\/dc21-2358","volume":"45","author":"MO Ruuskanen","year":"2022","unstructured":"Ruuskanen MO, Erawijantari PP, Havulinna AS, Liu Y, M\u00e9ric G, Tuomilehto J, et al. Gut Microbiome Composition Is Predictive of Incident Type 2 Diabetes in a Population Cohort of 5,572 Finnish Adults. Diabetes Care United States. 2022;45:811\u20138.","journal-title":"Diabetes Care United States"},{"key":"1427_CR60","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1038\/s41598-020-62224-3","volume":"10","author":"Q Li","year":"2020","unstructured":"Li Q, Chang Y, Zhang K, Chen H, Tao S, Zhang Z. Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci Rep Engl. 2020;10:5450.","journal-title":"Sci Rep Engl"},{"key":"1427_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00284-023-03219-x","volume":"80","author":"Q-L He","year":"2023","unstructured":"He Q-L, Wang H-C, Ma Y-K, Yang R-L, Dai Z-F, Yang J-N, et al. Changes in the Microbiota and their Roles in Patients with Type 2 Diabetes Mellitus. Curr Microbiol United States. 2023;80:132.","journal-title":"Curr Microbiol United States"},{"key":"1427_CR62","doi-asserted-by":"publisher","first-page":"108689","DOI":"10.1016\/j.diabres.2021.108689","volume":"173","author":"F Umirah","year":"2021","unstructured":"Umirah F, Neoh CF, Ramasamy K, Lim SM. Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: A systematic review. Diabetes Res Clin Pract Elsevier. 2021;173:108689.","journal-title":"Diabetes Res Clin Pract Elsevier"},{"key":"1427_CR63","doi-asserted-by":"crossref","unstructured":"Zhou W, Cheng Y, Zhu P, Nasser MI, Zhang X, Zhao M. Implication of Gut Microbiota in Cardiovascular Diseases. Oxid Med Cell Longev. John Wiley & Sons, Ltd; 2020;2020:5394096. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1155\/2020\/5394096.\u00a0 [Cited 6 Feb 2025].","DOI":"10.1155\/2020\/5394096"},{"key":"1427_CR64","doi-asserted-by":"crossref","unstructured":"Chen C, Liang Z, He Y, Gao Y, Ouyang S, Wang L et al. Bacteroides Fragilis Exacerbates T2D Vascular Calcification by Secreting Extracellular Vesicles to Induce M2 Macrophages. Adv Sci. John Wiley & Sons, Ltd; 2025;12:2410495. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/advs.202410495.\u00a0 [Cited 6 Feb 2026].","DOI":"10.1002\/advs.202410495"},{"key":"1427_CR65","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cca.2020.04.037","volume":"507","author":"W Chen","year":"2020","unstructured":"Chen W, Zhang S, Wu J, Ye T, Wang S, Wang P, et al. Butyrate-producing bacteria and the gut-heart axis in atherosclerosis. Clin Chim Acta Neth. 2020;507:236\u201341.","journal-title":"Clin Chim Acta Neth"},{"key":"1427_CR66","doi-asserted-by":"publisher","first-page":"761834","DOI":"10.3389\/fendo.2021.761834","volume":"12","author":"T Arora","year":"2021","unstructured":"Arora T, Tremaroli V. Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes. Front Endocrinol (Lausanne) Switz. 2021;12:761834.","journal-title":"Front Endocrinol (Lausanne) Switz"},{"key":"1427_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol Engl. 2019;15:261\u201373.","journal-title":"Nat Rev Endocrinol Engl"},{"key":"1427_CR68","first-page":"15","volume-title":"Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota","author":"W Fusco","year":"2023","unstructured":"Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Switzerland: Nutrients; 2023. p. 15."},{"key":"1427_CR69","first-page":"1","volume":"13","author":"A Nogal","year":"2021","unstructured":"Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes United States. 2021;13:1\u201324.","journal-title":"Gut Microbes United States"},{"key":"1427_CR70","doi-asserted-by":"publisher","unstructured":"Gao Y, Zhao T, Lv N, Liu S, Yuan T, Fu Y et al. Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study. Endocrine. 2024;85:1178\u201392. Available from: https:\/\/doi.org\/10.1007\/s12020-024-03828-x.","DOI":"10.1007\/s12020-024-03828-x"},{"key":"1427_CR71","doi-asserted-by":"publisher","first-page":"26835","DOI":"10.31083\/RCM26835","volume":"26","author":"R Zhou","year":"2025","unstructured":"Zhou R, Wu Q, Qian H, Wang L, Liu G, Zhang B, et al. Long-term Metformin Alters Gut Microbiota and Serum Metabolome in Coronary Artery Disease Patients After Percutaneous Coronary Intervention to Improve 5-year Prognoses: A Multi-omics Analysis. Rev Cardiovasc Med Singap. 2025;26:26835.","journal-title":"Rev Cardiovasc Med Singap"},{"key":"1427_CR72","doi-asserted-by":"publisher","first-page":"105137","DOI":"10.1016\/j.ebiom.2024.105137","volume":"103","author":"K An","year":"2024","unstructured":"An K, Jia Y, Xie B, Gao J, Chen Y, Yuan W, et al. Alterations in the gut mycobiome with coronary artery disease severity. EBioMedicine Neth. 2024;103:105137.","journal-title":"EBioMedicine Neth"},{"key":"1427_CR73","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1194\/jlr.R088989","volume":"60","author":"A Kriaa","year":"2019","unstructured":"Kriaa A, Bourgin M, Potiron A, Mkaouar H, Jablaoui A, G\u00e9rard P, et al. Microbial impact on cholesterol and bile acid metabolism: current status and future prospects. J Lipid Res United States. 2019;60:323\u201332.","journal-title":"J Lipid Res United States"},{"key":"1427_CR74","doi-asserted-by":"publisher","unstructured":"KalninaI, Gudra D, Silamikelis I, Viksne K, Roga A, Skinderskis E et al. Variations in the Relative Abundance of Gut Bacteria Correlate with Lipid Profiles in Healthy Adults. Microorganisms Switz; 2023;11. https:\/\/doi.org\/10.3390\/microorganisms11112656.","DOI":"10.3390\/microorganisms11112656"},{"key":"1427_CR75","doi-asserted-by":"publisher","first-page":"105150","DOI":"10.1016\/j.ebiom.2024.105150","volume":"104","author":"S Zhou","year":"2024","unstructured":"Zhou S, Liu L, Ye B, Xu Y, You Y, Zhu S, et al. Gut microbial metabolism is linked to variations in circulating non-high density lipoprotein cholesterol. EBioMedicine Neth. 2024;104:105150.","journal-title":"EBioMedicine Neth"},{"key":"1427_CR76","doi-asserted-by":"publisher","first-page":"5110276","DOI":"10.1155\/2021\/5110276","volume":"2021","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chu J, Hao W, Zhang J, Li H, Yang C, et al. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications. Mediators Inflamm United States. 2021;2021:5110276.","journal-title":"Mediators Inflamm United States"},{"key":"1427_CR77","doi-asserted-by":"publisher","first-page":"110168","DOI":"10.1016\/j.neuropharm.2024.110168","volume":"261","author":"S Yang","year":"2024","unstructured":"Yang S, Wang Y, Wu Z, Wang D, Zhang X, Hu S, et al. Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia. Neuropharmacol Engl. 2024;261:110168.","journal-title":"Neuropharmacol Engl"},{"key":"1427_CR78","doi-asserted-by":"publisher","first-page":"e0192622","DOI":"10.1128\/spectrum.01926-22","volume":"10","author":"S Li","year":"2022","unstructured":"Li S, Guo J, Liu R, Zhang F, Wen S, Liu Y, et al. Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis. Microbiol Spectr United States. 2022;10:e0192622.","journal-title":"Microbiol Spectr United States"},{"key":"1427_CR79","doi-asserted-by":"crossref","unstructured":"Drapkina OM, Ashniev GA, Zlobovskaya OA, Yafarova AA, Dementeva EV, Kaburova AN, et al. Diversities in the Gut Microbial Patterns in Patients with Atherosclerotic Cardiovascular Diseases and Certain Heart Failure Phenotypes. Biomedicines. Switzerland; 2022. p. 10.","DOI":"10.3390\/biomedicines10112762"},{"key":"1427_CR80","first-page":"1376","volume":"359","author":"CA Thaiss","year":"2018","unstructured":"Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Sci United States. 2018;359:1376\u201383.","journal-title":"Sci United States"},{"key":"1427_CR81","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17474124.2017.1343143","volume":"11","author":"M Vancamelbeke","year":"2017","unstructured":"Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol Engl. 2017;11:821\u201334.","journal-title":"Expert Rev Gastroenterol Hepatol Engl"},{"key":"1427_CR82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","volume":"19","author":"F Di Vincenzo","year":"2024","unstructured":"Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med Italy. 2024;19:275\u201393.","journal-title":"Intern Emerg Med Italy"},{"key":"1427_CR83","first-page":"113","volume":"2","author":"AVC Pilar","year":"2011","unstructured":"Pilar AVC, Coombes BK. A Fresh Look at the Type III Secretion System: Two-Step Model of Effector Translocation in Pathogenic Bacteria. Front Microbiol Switz. 2011;2:113.","journal-title":"Front Microbiol Switz"},{"key":"1427_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mib.2019.12.001","volume":"54","author":"A Serapio-Palacios","year":"2020","unstructured":"Serapio-Palacios A, Finlay BB. Dynamics of expression, secretion and translocation of type III effectors during enteropathogenic Escherichia coli infection. Curr Opin Microbiol Engl. 2020;54:67\u201376.","journal-title":"Curr Opin Microbiol Engl"},{"key":"1427_CR85","doi-asserted-by":"publisher","first-page":"e12938","DOI":"10.1111\/cmi.12938","volume":"20","author":"D Truong","year":"2018","unstructured":"Truong D, Boddy KC, Canadien V, Brabant D, Fairn GD, D\u2019Costa VM, et al. Salmonella exploits host Rho GTPase signalling pathways through the phosphatase activity of SopB. Cell Microbiol United States. 2018;20:e12938.","journal-title":"Cell Microbiol United States"},{"key":"1427_CR86","doi-asserted-by":"publisher","unstructured":"Slater SL, S\u00e5gfors AM, Pollard DJ, Ruano-Gallego D, Frankel G. The Type III Secretion System of Pathogenic Escherichia coli. In: Frankel G, Ron EZ, editors. Escherichia coli, a Versatile Pathog. Cham: Springer International Publishing; 2018. pp. 51\u201372. Available from: https:\/\/doi.org\/10.1007\/82_2018_116.","DOI":"10.1007\/82_2018_116"},{"key":"1427_CR87","doi-asserted-by":"crossref","unstructured":"Contreras CA, Hazen TH, Guadarrama C, Cervantes-Rivera R, Ochoa TJ, Vinuesa P et al. Phenotypic diversity of type III secretion system activity in enteropathogenic Escherichia coli clinical isolates. J Med Microbiol. Microbiology Society; 2024;73:001907. Available from: https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001907.\u00a0 [Cited 6 Feb 2025].","DOI":"10.1099\/jmm.0.001907"},{"key":"1427_CR88","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12941-017-0188-y","volume":"16","author":"R Slinger","year":"2017","unstructured":"Slinger R, Lau K, Slinger M, Moldovan I, Chan F. Higher atypical enteropathogenic Escherichia coli (a-EPEC) bacterial loads in children with diarrhea are associated with PCR detection of the EHEC factor for adherence 1\/lymphocyte inhibitory factor A (efa1\/lifa) gene. Ann Clin Microbiol Antimicrob Engl. 2017;16:16.","journal-title":"Ann Clin Microbiol Antimicrob Engl"},{"key":"1427_CR89","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/AEM.00537-13","volume":"79","author":"A Cabal","year":"2013","unstructured":"Cabal A, G\u00f3mez-Barrero S, Porrero C, B\u00e1rcena C, L\u00f3pez G, Cant\u00f3n R, et al. Assessment of virulence factors characteristic of human Escherichia coli pathotypes and antimicrobial resistance in O157:H7 and non-O157:H7 isolates from livestock in Spain. Appl Environ Microbiol United States. 2013;79:4170\u20132.","journal-title":"Appl Environ Microbiol United States"},{"key":"1427_CR90","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2174\/0109298673335863240829060545","volume":"32","author":"M Mohammadi-Kordkhayli","year":"2025","unstructured":"Mohammadi-Kordkhayli M, Mousavi MJ, Camara-Lemarroy CR, Noorbakhsh F, Saboor-Yaraghi AA. Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation. Curr Med Chem United Arab Emirates. 2025;32:6547\u201362.","journal-title":"Curr Med Chem United Arab Emirates"},{"key":"1427_CR91","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1172\/JCI62746","volume":"122","author":"EM Mallick","year":"2012","unstructured":"Mallick EM, McBee ME, Vanguri VK, Melton-Celsa AR, Schlieper K, Karalius BJ, et al. A novel murine infection model for Shiga toxin-producing Escherichia coli. J Clin Invest United States. 2012;122:4012\u201324.","journal-title":"J Clin Invest United States"},{"key":"1427_CR92","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s44318-025-00412-5","volume":"44","author":"HW Yeap","year":"2025","unstructured":"Yeap HW, Goh GR, Rosli SN, Pung HS, Giogha C, Eng VV, et al. A bacterial network of T3SS effectors counteracts host pro-inflammatory responses and cell death to promote infection. EMBO J Engl. 2025;44:2424\u201345.","journal-title":"EMBO J Engl"},{"key":"1427_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nat Engl. 2011;472:57\u201363.","journal-title":"Nat Engl"},{"key":"1427_CR94","doi-asserted-by":"publisher","first-page":"e0281730","DOI":"10.1371\/journal.pone.0281730","volume":"18","author":"E Nakamura","year":"2023","unstructured":"Nakamura E, Maekawa K, Saito Y, Matsumoto T, Ogawa M, Komohara Y, et al. Altered choline level in atherosclerotic lesions: Upregulation of choline transporter-like protein 1 in human coronary unstable plaque. PLoS One United States. 2023;18:e0281730.","journal-title":"PLoS One United States"},{"key":"1427_CR95","doi-asserted-by":"publisher","first-page":"166984","DOI":"10.1016\/j.bbadis.2023.166984","volume":"1870","author":"H Chen","year":"2024","unstructured":"Chen H, Qian Y, Jiang C, Tang L, Yu J, Zhang L, et al. Butyrate ameliorated ferroptosis in ulcerative colitis through modulating Nrf2\/GPX4 signal pathway and improving intestinal barrier. Biochim Biophys acta Mol basis Dis Neth. 2024;1870:166984.","journal-title":"Biochim Biophys acta Mol basis Dis Neth"},{"key":"1427_CR96","doi-asserted-by":"publisher","first-page":"115765","DOI":"10.1016\/j.bcp.2023.115765","volume":"216","author":"N Dubois","year":"2023","unstructured":"Dubois N, Mu\u00f1oz-Garcia J, Heymann D, Renodon-Corni\u00e8re A. High glucose exposure drives intestinal barrier dysfunction by altering its morphological, structural and functional properties. Biochem Pharmacol Engl. 2023;216:115765.","journal-title":"Biochem Pharmacol Engl"},{"key":"1427_CR97","first-page":"1079","volume":"163","author":"D Zeevi","year":"2015","unstructured":"Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell United States. 2015;163:1079\u201394.","journal-title":"Cell United States"},{"key":"1427_CR98","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","volume":"51","author":"S Sanna","year":"2019","unstructured":"Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, V\u00f5sa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet United States. 2019;51:600\u20135.","journal-title":"Nat Genet United States"},{"key":"1427_CR99","doi-asserted-by":"crossref","unstructured":"Koh A, Molinaro A, St\u00e5hlman M, Khan MT, Schmidt C, Manner\u00e5s-Holm L et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell. 2018;175:947\u2013961.e17. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0092867418313060.","DOI":"10.1016\/j.cell.2018.09.055"},{"key":"1427_CR100","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-025-09263-w","volume":"645","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo A, Robles-Vera I, Ma\u00f1anes D, Gal\u00e1n M, Femen\u00eda-Mui\u00f1a M, Redondo-Urzainqui A, et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nat Engl. 2025;645:254\u201361.","journal-title":"Nat Engl"},{"key":"1427_CR101","doi-asserted-by":"publisher","unstructured":"Wang W, Zhang L, Zhou Y. Causal effects of gut microbiota on diabetic kidney disease: insights from 16S rRNA sequencing and bidirectional Mendelian randomization. Ren Fail. Taylor & Francis; 2025;47:2566381. Available from: https:\/\/doi.org\/10.1080\/0886022X.2025.2566381.","DOI":"10.1080\/0886022X.2025.2566381"},{"key":"1427_CR102","doi-asserted-by":"crossref","unstructured":"Hoogeveen EK, The Epidemiology of Diabetic Kidney Disease. Kidney Dial. 2022;2:433\u201342. Available from: https:\/\/www.mdpi.com\/2673-8236\/2\/3\/38.","DOI":"10.3390\/kidneydial2030038"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01427-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:05:19Z","timestamp":1779357919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01427-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01427-x","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies with human and animal subjects are published and followed ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"52"}}